DUXAP8 and colorectal carcinoma: Further assays showed that DUXAP8 knockdown resulted in the inhibition of EZH2 and H3K27me3 binding to the E‐cadherin promoter, suggesting that DUXAP8 interacts with EZH2, contributing to E‐cadherin levels decrease and CRC cell proliferation [11].